These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 31714156)

  • 41. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
    Sutherland CL; Chalupny NJ; Cosman D
    Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
    Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
    Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor.
    Kaur K; Safaie T; Ko MW; Wang Y; Jewett A
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
    Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
    Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
    Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
    J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
    Zhao L; Wang WJ; Zhang JN; Zhang XY
    Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells.
    Lanier LL; Corliss BC; Wu J; Leong C; Phillips JH
    Nature; 1998 Feb; 391(6668):703-7. PubMed ID: 9490415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
    Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
    Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
    Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
    J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.
    Takayama T; Tahara H; Thomson AW
    Transplantation; 2001 May; 71(9):1334-40. PubMed ID: 11397973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.
    Ou ZL; Luo Z; Wei W; Liang S; Gao TL; Lu YB
    RNA Biol; 2019 Nov; 16(11):1592-1603. PubMed ID: 31402756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
    Gooneratne SL; Center RJ; Kent SJ; Parsons MS
    Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer.
    Ciszak L; Kosmaczewska A; Werynska B; Szteblich A; Jankowska R; Frydecka I
    Oncol Rep; 2009 Jan; 21(1):173-84. PubMed ID: 19082459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.